**PURPOSE:** Mesenchymal stem cells deriving from bone marrow and adipose tissue have immunomodulatory effects and low immunogenicity. Cell therapy using donor-derived bone marrow cells is already being used clinically and has reduced the burden of immunosuppressive drugs in vascularized composite allotransplantation (VCA) patients. However, the quantity of donor-derived bone marrow cells that can be effectively harvested from an individual donor is limited. Adipose-derived stem cells (ASCs) represent another clinically useful source of cell therapy for allotransplantation. This study was designed to investigate whether ASCs treatment could prolong graft survival in a porcine large animal model.

**METHODS:** Full-major histocompatibility complex (MHC) mismatched heterotopic hind-limb transplantations were performed in MGH mini-swine. Animals receiving no therapy and animals treated with tacrolimus for the initial 30 days served as control and standard therapy group, respectively. Experimental animals were treated with a standard immunosuppressive protocol including tacrolimus for 30 days, followed by ASC therapy (donor-derived ASCs \[1.0x10\^6 cells/kg\] administered intravenously in recipients at post-operative day 7). Allograft survival was compared across the different treatment protocols.

**RESULTS:** Six allogenic hind limb transplantations in the mini-swine were performed in three groups. The control group reached Banff grade 4 acute rejection by an average of 7.5 days after transplantation. Allografts treated with ASCs demonstrated grade 4 rejection on day 119 and demonstrated rejection-free survival over 200 days postoperatively, which was longer than the standard therapy group. The long-term survivor of the ASCs therapy group showed donor-specific unresponsiveness and regulatory T cells upregulation.

**CONCLUSION:** Early results of ongoing *in vivo* experimentation show promising results of ASC therapy in prolonging acute rejection-free VCA survival across a full MHC mismatch. Achieved immune tolerance by cellular immunomodulation is considered to prolong allograft survival.
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